united healthcare semaglutide coverage President Trump announced that Medicare will cover (Wegovy) and tirzepatide (Zepbound) for weight management indications for people with obesity. Our senior staff writer Kristen Monaco unitedhealthcare semaglutide coverage United healthcare

D., Kim, H

Clinical trials show average weight loss of 15-18% of body weight over 68 weeks, though individual results range from 5-50+ pounds depending on starting weight, adherence, diet, and exercise

The low incidence of hypoglycemia is consistent with the glucose-dependent mechanism of action of GLP1 receptor agonists, with only 3 events reported overall, all of which were mild

These results have meaningful clinical and policy implications for Asian countries, where lower BMI thresholds define obesity compared to other populations

Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival